Yahoo Web Search

Search results

1. • 

     Teva and Medincell’s schizophrenia drug meets main goal of late-stage study

     KFGO· 6 days ago

     (Reuters) -Israel-based Teva Pharmaceuticals and French partner Medincell said on Wednesday their...

2. • In Vivo Reactive Astrocyte Imaging in Patients With Schizophrenia Using [18F]THK5351

     Journal of the American Medical Association· 6 days ago

     This case-control study investigates the in vivo imaging of reactive astrocytes and their association with positive symptoms in patients with schizophrenia

3. • 

     NeuShen begins dosing for Phase I trial of schizophrenia treatment

     Clinical Trials Arena via Yahoo Finance· 6 days ago

     Developed from NeuShen’s small molecule R&D platform, NS-136 has shown efficacy against both...

4. • ...First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for...

     NBC 17 Raleigh· 6 days ago

     M4 PAM presents a novel approach to treating schizophrenia, with potential benefits in alleviating negative symptoms and cognitive impairment ...

5. • 

     'Impressive' New Data on Novel Schizophrenia Hopeful KarXT

     Medscape· 7 days ago

     The novel investigational antipsychotic KarXT was effective and well tolerated in adults with ...

6. • ...olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia -...

     Benzinga· 6 days ago

     The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total

7. • 

     Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial

     Clinical Trials Arena via Yahoo Finance· 5 days ago

     The Phase III SOLARIS trial has revealed promising results for TEV...The study met its primary...

8. • Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

     Zacks· 6 days ago

     Free Report) reported first-quarter 2024 earnings of 10 cents per share, beating the Zacks Consensus Estimate of 4 cents. Acadia recorded total revenues of $205.8 million, which missed the Zacks ...

9. • 

     TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up

     Zacks via Yahoo Finance· 5 days ago

     TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for...

10. • Raymond James Cuts HLS Therapeutics (TSE:HLS) Price Target to C$4.00

      ETF DAILY NEWS· 2 days ago

      HLS Therapeutics (TSE:HLS – Free Report) had its target price cut by Raymond James from C$5.00 to C$4.00 in a report issued on Friday morning, BayStreet.CA reports. A number of other research ...